Research ArticleHeart Failure

Nicotinamide for the treatment of heart failure with preserved ejection fraction

See allHide authors and affiliations

Science Translational Medicine  10 Feb 2021:
Vol. 13, Issue 580, eabd7064
DOI: 10.1126/scitranslmed.abd7064

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Diet and diastolic dysfunction

Increasing nicotinamide adenine dinucleotide (NAD+) can mimic some of the benefits of caloric restriction, which improves cardiac hypertrophy, metabolic dysfunction, and exercise capacity. Abdellatif et al. investigated whether nicotinamide, the NAD+ precursor, could alleviate diastolic dysfunction associated with heart failure with preserved ejection fraction (HFpEF). Rodent models of aging, metabolic syndrome, and hypertension (risk factors of HFpEF) showed improvements with NAM supplementation, which the authors linked to increased deacetylation of proteins involved in cardiac myocyte stiffness and relaxation. Greater dietary intake of NAD+ precursors was associated with lower cardiac mortality risk and decreased blood pressure in humans. Thus, NAD+ precursors may be a potential therapeutic strategy for HFpEF.

View Full Text

Stay Connected to Science Translational Medicine